Z. Piotrowska

发表

Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group.

T. Burns, A. Shaw, C. Lovly, 2020, Clinical lung cancer.

A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.

S. Digumarthy, L. Sequist, A. Shaw, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.

K. Ramchandran, J. Neal, H. Wakelee, 2021, Clinical lung cancer.

Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer.

L. Sequist, J. Engelman, B. Drapkin, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer

Anna L. Brown, Chuong D. Hoang, A. Panchenko, 2020, Cell reports medicine.

O10.3Rociletinib: an oral, irreversible, highly selective small molecule inhibitor of mutant EGFR including T790M

J. Neal, H. Wakelee, L. Sequist, 2015 .

Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma.

L. Sequist, F. Fintelmann, B. Jahagirdar, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Defective mismatch-repair in patients with multiple primary tumours including colorectal cancer.

H. Olsson, M. Nilbert, B. Halvarsson, 2003, European journal of cancer.

Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).

H. Wakelee, L. Sequist, S. Ou, 2015 .

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer

M. Kris, C. Azzoli, J. Shrager, 2021, JCO precision oncology.

Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.

L. Sequist, H. Willers, M. Khandekar, 2018, The oncologist.

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM

B. Bernstein, Y. Drier, L. Sequist, 2017, Clinical Cancer Research.

Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine

M. Nilbert, B. Halvarsson, M. Planck, 2003, Cancer.

Rhinoviruses Are a Major Cause of Wheezing and Hospitalization in Children Less Than 2 Years of Age

E. Shapiro, J. Kahn, M. Landry, 2009, The Pediatric infectious disease journal.

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.

M. Socinski, X. Le, J. Clarke, 2020 .

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib

A. Shaw, R. Heist, A. Muzikansky, 2022, JTO clinical and research reports.

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC

M. Mino‐Kenudson, L. Sequist, R. Heist, 2022, JTO clinical and research reports.

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors

D. Leaf, D. Iberri, Douglas B. Johnson, 2019, American journal of hematology.

Targeting EGFR Exon 20 Insertions in NSCLC: Recent Advances and Clinical Updates

L. Sequist, C. Meador, Z. Piotrowska, 2021 .

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

S. Digumarthy, L. Sequist, J. Engelman, 2016, JAMA oncology.

ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?

J. Gainor, Z. Piotrowska, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

There Is No Unmet Need for Another Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Inhibitor for Metastatic NSCLC.

I. Dagogo-Jack, Z. Piotrowska, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer

S. Lim, B. Cho, R. Soo, 2022, Therapeutic advances in medical oncology.

Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer

Jie Yang, P. Jänne, Gregory Riely, 2022, Expert review of anticancer therapy.

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

G. Getz, A. Iafrate, L. Sequist, 2016, Nature Medicine.

Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.

M. Mino‐Kenudson, L. Sequist, J. Engelman, 2021, Cancer cell.

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

L. Sequist, J. Engelman, J. Settleman, 2019, Cell reports.

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Ash A. Alizadeh, Maximilian Diehn, Aaron M. Newman, 2016, Nature Communications.

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

M. Mino‐Kenudson, J. Neal, H. Wakelee, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial.

J. Neal, Gregory Riely, D. Costa, 2021, Cancer discovery.

ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.

L. Sequist, S. Ramalingam, Z. Piotrowska, 2020 .

Rociletinib in EGFR-mutated non-small-cell lung cancer.

J. Neal, H. Wakelee, L. Sequist, 2015, The New England journal of medicine.

Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).

M. Socinski, E. Smit, V. Lee, 2021, Journal of Clinical Oncology.

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

S. Digumarthy, Y. Yagi, C. Azzoli, 2016, Clinical Cancer Research.

Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review.

L. Sequist, Z. Piotrowska, 2016, JAMA oncology.

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2018, Cancer discovery.

Role of imaging biomarkers in mutation-driven non-small cell lung cancer

S. Digumarthy, J. Lennerz, D. Mendoza, 2020, World journal of clinical oncology.

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Joshua M. Korn, J. Korn, P. Hammerman, 2019, Oncogene.

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care

L. Sequist, A. Dastur, J. Engelman, 2017, Cell reports.

Epidermal Growth Factor Receptor–Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options

L. Sequist, Z. Piotrowska, 2015, Cancer journal.

Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.

S. Digumarthy, A. Iafrate, L. Sequist, 2018, JCO precision oncology.

Patient-specific tumor growth trajectories determine persistent and resistant cancer cell populations during treatment with targeted therapies.

L. Sequist, H. Paganetti, Y. Maruvka, 2019, Cancer research.

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Ash A. Alizadeh, Aaron M. Newman, Kathleen A. Durkin, 2016, Nature Communications.

APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer

Christopher J. Ott, Jake June-Koo Lee, Chang S. Chan, 2021, bioRxiv.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2015, Cancer discovery.

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

L. Sequist, S. Kobayashi, D. Costa, 2018, Clinical Cancer Research.

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.

A. Iafrate, M. Mino‐Kenudson, A. Shaw, 2017, JCO precision oncology.

Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer.

L. Sequist, Z. Piotrowska, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy

A. Niemierko, L. Sequist, H. Willers, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

L. Sequist, J. Engelman, Haichuan Hu, 2015, Clinical Cancer Research.

Modeling Resistance and Recurrence Patterns of Combined Targeted–Chemoradiotherapy Predicts Benefit of Shorter Induction Period

L. Sequist, H. Paganetti, H. Willers, 2019, Cancer Research.

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

C. Paweletz, P. Jänne, G. Shapiro, 2020, Clinical Cancer Research.

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions

C. Azzoli, L. Sequist, A. Shaw, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

S. Digumarthy, J. Neal, H. Wakelee, 2023, JTO clinical and research reports.

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

Sean P. Brown, C. Azzoli, D. Cahill, 2018, Cancer discovery.

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer

Julie M. Batten, S. Digumarthy, A. Iafrate, 2018, JCO precision oncology.

Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.

S. Digumarthy, L. Sequist, J. Lennerz, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib

J. Riess, B. Cho, I. Okamoto, 2021, Annals of Oncology.

Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review.

L. Sequist, Z. Piotrowska, A. Piper-Vallillo, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience

J. Neal, H. Wakelee, L. Sequist, 2022, JTO clinical and research reports.

Rhinovirus-associated wheezing and asthma in young children.

Z. Piotrowska, 2009 .

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).

Philip Smith, J. Riess, B. Cho, 2021, Clinical lung cancer.

MET amplification (amp) as a resistance mechanism to osimertinib.

C. Azzoli, L. Sequist, A. Shaw, 2017 .

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.

J. Neal, H. Wakelee, L. Sequist, 2021, Clinical lung cancer.

Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions

P. Jänne, J. Neal, Gregory Riely, 2019, Annals of Oncology.

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor‐Mutant Lung Cancer

Fabian M. Troschel, Amita Sharma, S. Digumarthy, 2019, The oncologist.

Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review

C. Meador, Z. Piotrowska, 2023, Translational lung cancer research.

The Role of Liquid Biopsies in Lung Cancer Screening.

L. Sequist, I. Dagogo-Jack, Z. Piotrowska, 2017, Seminars in roentgenology.

Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.

S. Groshen, C. Paweletz, P. Jänne, 2019, Journal of Clinical Oncology.

Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).

M. Socinski, E. Smit, V. Lee, 2022, Journal of Clinical Oncology.

Abstract CT184: Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA (ctDNA) in the phase 1/2 SYMPHONY study

K. Goto, D. Spigel, K. Reckamp, 2022, Cancer Research.

Abstract P230: A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with EGFR-mutant non-small cell lung cancer (NSCLC)

D. Planchard, D. Camidge, K. Goto, 2021, Poster Presentations - Proffered Abstracts.

Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?

L. Sequist, Z. Piotrowska, 2015, The oncologist.

Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy.

S. Digumarthy, M. Mino‐Kenudson, L. Sequist, 2014 .

Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma.

L. Sequist, A. Farago, Z. Piotrowska, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy.

S. Digumarthy, C. Azzoli, M. Mino‐Kenudson, 2017, International journal of radiation oncology, biology, physics.

P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib

J. Riess, Paul D. Smith, I. Okamoto, 2021 .

Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.

J. Neal, H. Wakelee, J. Riess, 2020, Journal of Clinical Oncology.

Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

L. Sequist, S. Kobayashi, D. Costa, 2020, Clinical Cancer Research.

Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.

L. Sequist, J. Engelman, A. Shaw, 2015 .

P2.06-007 A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non–Small Cell Lung Cancer (NSCLC): Topic: Phase I/II Trials

P. Jänne, J. Neal, D. Costa, 2017 .

Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates.

L. Sequist, C. Meador, Z. Piotrowska, 2021, Cancer discovery.

Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer

Atul Padole, S. Digumarthy, L. Sequist, 2019, Cancers.

P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy

J. Riess, Paul D. Smith, P. Jewsbury, 2019, Journal of Thoracic Oncology.

Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.

J. Neal, Gregory Riely, D. Costa, 2019, Journal of Clinical Oncology.

1001P Epidermal growth factor receptor (EGFR) testing and treatment patterns associated with diagnosis of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) in the US

S. Ou, Y. Wu, Z. Piotrowska, 2022, Annals of Oncology.

Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

S. Groshen, C. Paweletz, H. Wakelee, 2022, Journal of Clinical Oncology.

OA 09.01 Characterizing the Genomic Landscape of EGFR C797S in Lung Cancer Using ctDNA Next-Generation Sequencing

L. Sequist, S. Gettinger, T. Owonikoko, 2017 .

Therapy-induced APOBEC3A drives evolution of persistent cancer cells

Christopher J. Ott, Chang S. Chan, M. Lawrence, 2023, Nature.

1345P Preliminary safety and activity of CLN-081 in NSCLC with EGFR exon 20 insertion mutations (Ins20)

L. Zawel, D. Witter, N. Tchekmedyian, 2020 .

1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)

P. Jänne, J. Neal, Gregory Riely, 2020 .

P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC

P. Jänne, J. Neal, Gregory Riely, 2018, Journal of Thoracic Oncology.

Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC).

C. Azzoli, M. Mino‐Kenudson, L. Sequist, 2015 .

COVID-19 Infection in a Lung Cancer Patient Population: Incidence, Presentation and Alternative Diagnostic Considerations

S. Digumarthy, L. Sequist, R. Heist, 2020, JTO Clinical and Research Reports.

Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations

S. Digumarthy, L. Sequist, R. Heist, 2020, JTO Clinical and Research Reports.

OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy

Duc Minh Nguyen, P. Jänne, J. Neal, 2021, Journal of Thoracic Oncology.

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

L. Sequist, D. Costa, G. Oxnard, 2018, Clinical Cancer Research.

Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer.

A. Iafrate, M. Mino‐Kenudson, L. Sequist, 2017, JCO precision oncology.

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

S. Digumarthy, L. Sequist, J. Engelman, 2016, JAMA oncology.

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

L. Sequist, J. Engelman, Haichuan Hu, 2015, Clinical Cancer Research.

First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC).

P. Jänne, J. Neal, Gregory Riely, 2018 .

Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.

J. Neal, H. Wakelee, L. Sequist, 2019, Journal of Clinical Oncology.

End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.

L. Sequist, R. Heist, J. Temel, 2016, Journal of palliative medicine.

Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue

A. Hata, Z. Piotrowska, 2020, Clinical Cancer Research.

Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.

L. Sequist, A. Shaw, R. Heist, 2018 .

EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).

J. Neal, H. Wakelee, R. Herbst, 2023, Journal of Clinical Oncology.

FP01.05 The ASCENT Trial: A Phase II Study of Neoadjuvant/Adjuvant Afatinib, Chemoradiation +/- Surgery for Stage III EGFR-Mutant NSCLC

P. Jänne, R. Mak, M. Mino‐Kenudson, 2021 .